Vertex Pharmaceuticals, Inc. (VRTX) Blows Up Q3 Estimates
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $514.99 --0%
Revenue Growth %: +10.7%
Financial Fact:
Total revenues: 413.78M
Today's EPS Names:
NEOV, MANU, CTAS, More
Revenue Growth %: +10.7%
Financial Fact:
Total revenues: 413.78M
Today's EPS Names:
NEOV, MANU, CTAS, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.70, $0.53 better than the analyst estimate of $0.17. Revenue for the quarter came in at $659.2 million versus the consensus estimate of $343.42 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VRTX) PT Raised to $640 at Jefferies
- Worthington Industries (WOR) Tops Q1 EPS by 7c
- Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
